NFKB1 and liver cancer: The review also explores new therapeutic approaches targeting inflammatory pathways, including novel compounds and synthetic agents, such as IL-6 receptor antagonist and NF-κB pathway blockers and their potential for effectively treating and preventing liver cancer.